Previous 10 | Next 10 |
Amryt (NASDAQ:AMYT) will file a Formal Dispute Resolution Request to the U.S. FDA in response to a Complete Response Letter received in February for Oleogel-S10 (Filsuvez). Oleogel-S10 is under investigation for Dystrophic and Junctional Epidermolysis Bullosa (EB), a rare, genetic s...
Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA Filsuvez® rece ntly approved by the E uropean C ommission for the treatment of EB DUBLIN, Ireland, and Boston MA, Ju ne 24 , 2022, Amryt (Nasdaq: AMYT)...
The European Commission (EC) approved Amryt's ( NASDAQ: AMYT ) Filsuvez to treat partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare disease in which the skin becomes fragile an...
European Commission Approves Filsuvez® for the t reatment of Dystrophic and Junctional EB Filsuvez® w ill be the first and only approved treatment for EB Patients DUBLIN, Ireland, and Boston M A, June 23 ,...
Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022 Data from the MPOWERED OLE and f irst presentation of open-label extension (OLE) d ata from 2 nd year ...
Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 DUBLIN, Ireland, and Boston MA, June 8 , 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biophar...
P osting of A nnual Report and Notice of AGM DUBLIN, Ireland, and Boston MA, June 1 , 2022 , Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rar...
In a bear market, Krystal still shows that strong execution can be lucrative. They will file a BLA this quarter. The market potential is huge. For further details see: Krystal Biotech: High Potential, Buy-At-Dips Stock
Amryt Announces Details of EMA Contingent Value Rights Payment DUBLIN, Ireland, and Boston MA, May 17, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, ...
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, May 11, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an upda...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...